

# Product Information

## MemDX™ Membrane Protein Human CD19 (CD19 molecule) without tag for Antibody

### Discovery

Cat. No.: **MP0181X**

This product is for research use only and is not intended for diagnostic use.

This product is a 61.1 kDa Human CD19 membrane protein expressed in *in vitro* wheat germ expression system. The protein is for research use only and is not approved for use in humans or in clinical diagnosis.

### Product Specifications

#### Host Species

Human

#### Target Protein

CD19

#### Protein Length

Full-length

#### Molecular Weight

61.1 kDa

#### TMD

1

#### Sequence

MPPPRLLFFLLFLTPMEVRPEEPLVVKVEEGDNAVLQCLKGTSDGPTQQLTWSRESPLKPFLKLSLGLPGLGIHMRPLAIWLFIFNV

### Product Description

#### Application

Antibody Production

#### Expression Systems

*in vitro* wheat germ expression system

#### Tag

NO

#### Protein Format

Liposome

#### Form

Liquid

**Purification**

None

**Buffer**

25 mM Tris-HCl of pH8.0 containing 2% glycerol

**Storage**

Store at +4°C for up to one week or several months at -80°C

**Target****Target Protein**

CD19

**Full Name**

CD19 molecule

**Introduction**

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms

**Alternative Names**

B4; MGC12802; B-lymphocyte antigen CD19; CD19 antigen

**Gene ID**

[930](#)

**UniProt ID**

[P15391](#)